FOLKS studying CTIX....you used to have days or

New Post Public Reply Private Reply Replies (0) Message Board
biomanbaba

FOLKS studying CTIX....you used to have days or weeks.......you now have HOURS AND DAYS only

First Patients Recruited and Enrolled in Cellceutix Clinical Trial of Novel Anti-Cancer Drug Kevetrin

Elsevier Business Intelligence  Reports Cellceutix “ Developing A Still-Secret Prodrug For Psoriasis” and a “Heralded Cancer Candidate”

BEVERLY, MA – October 29, 2012-- Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to report that the first patients have been recruited and enrolled for the clinical trials of Kevetrin™, the Company’s novel cancer drug in development.  The clinical trials are being conducted on patients with advanced solid tumors at Harvard University’s Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center.

Based on dialogue with the clinical sites, the Company anticipates updating shareholders next week that dosing of the first patient has been administered.

“We are extremely pleased to hear that the first patients will begin therapy with Kevetrin™ in a matter of days,” said Dr. Krishna Menon, Chief Scientific Officer at Cellceutix.  “Not only is this is a substantial milestone for Cellceutix and its shareholders, but we feel it is important to the field of oncology.  As a novel compound that directly impacts p53, the “Guardian Angel of the Human Genome,” we look forward to a steady patient enrollment and future outcomes that potentially could change the landscape of cancer therapeutics.

Elsevier Business Intelligence

Cellceutix announced that Elsevier Business Intelligence has released a profile article on the Company for its latest edition of its publication “Start Up: Emerging Medical Ventures.”

Elsevier, a division of Reed Elsevier Group PLC, is the world’s leading provider of science and health information, serving more than 30 million scientists, students and health and information professionals worldwide.

In the article, Elsevier’s Deborah Erickson discusses the uniqueness of the Company’s Prurisol™ as a new therapeutic candidate for psoriasis, and the clinical trials at Dana-Farber Cancer Center and Beth Israel Deaconess on Kevetrin™ as a novel, p53-activating anti-cancer drug.  Regularly referencing Cellceutix as “anything but a normal start-up,” the write-up provides a succinct overview of the Company, its “all-star” advisory staff and offers insight into Kevetrin and Prurisol.

Shareholders and interested parties are encouraged to view the article at: http://cellceutix.com/category/in-the-news/

“We are very pleased to have been approached by Elsevier.  They have a tremendous global outreach and the additional exposure is positive for our company,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix.  “I found it particularly interesting how attracted they were to Prurisol and the incredible potential that they see for the drug.  Because of the p53 connection and strong possibilities for Kevetrin™, many people overlook how impactful and valuable Prurisol can be as well.”

About Kevetrin™

As a completely new class of chemistry in medicine, Kevetrin™ has significant potential to be a major breakthrough in the treatment of solid tumors. Mechanism of action studies showed Kevetrin's unique ability to affect both wild and mutant types of p53 (often referred to as the "Guardian Angel Gene" or the "Guardian Angel of the Human Genome") and that Kevetrin strongly induced apoptosis (cell death), characterized by activation of Caspase 3 and cleavage of PARP. Activation of p53 also induced apoptosis by inducing the expression of p53 target gene PUMA. p53 is an important tumor suppressor that acts to restrict proliferation by inducing cell cycle checkpoints, apoptosis, or cellular senescence.

In more than 50 percent of all human carcinomas, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are greater than 10 million people with tumors that contain inactivated p53, while a similar number have tumors in which the p53 pathway is partially abrogated by inactivation of other signaling components. This has left cancer researchers with the grand challenge of searching for therapies that could restore the protein's protective function, which Kevetrin appears to be doing the majority of the time.

The clinical trial titled, "A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors," is available at: http://clinicaltrials.gov/ct2/show/NCT0166400...amp;rank=1

About Prurisol

Prurisol is a small molecule, acting on the principles of immune modulation and PRINS reduction that has been found to be effective against psoriasis in animal models, both in induced psoriasis as well as a xenograft model with human psoriatic tissue.  It is 25% orally bioavailable allowing the potential for oral administration. Prurisol was studied in SCID mice that were irradiated then engrafted with human psoriatic tissue by inserting human psoriatic tissue under the skin using a trocar.   The results of the research showed that Prurisol significantly reduced all psoriatic endpoints measured relative to controls.  More detailed information and images of the animal models can be found at:   http://cellceutix.com/prurisol/

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About Cellceutix

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". It is an emerging bio-pharmaceutical company focused on the development of its pipeline of compounds targeting areas of unmet medical need. Our flagship compound, Kevetrin™, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers which have proven resistant to today's cancer therapies (drug-resistant cancers). Cellceutix also owns the rights to seven other drug compounds, including KM-133, which is in development for psoriasis, and KM-391 for the treatment of the core symptoms of autism. More information is available on the Cellceutix web site at www.cellceutix.com.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Factors that may impact Cellceutix's success are more fully disclosed in Cellceutix's most recent public filings with the U.S. Securities and Exchange Commission.


Cellceutix Corp.
Leo Ehrlich
(978) 236-8717
info@cellceutix.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 15

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 116

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
Midea’s SC26 Cooling Pitch Targets AI Build Delays

Updated Category News Views 80

Heat is the uninvited partner in every AI build, and Midea is making a sensible argument that nobody gets paid for racks sitting idle while piping crews wrestle with a complicated cooling plant. At SC26 in Chicago, held November 17 through 19, the company made its North American debut for a modular prefabricated AI data-center cooling setup built around a magnetic coolant...

Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 113

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 36

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 215

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 119

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 14

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
VIGGO’s Mix1Pro Tests Practical Commercial Cleaning

Updated Category News Views 61

A cleaning robot earns its keep in the ugly corners, not under convention-center lights. VIGGO used the ISSA Show North America gathering in Las Vegas, held November 17–19, 2026, to introduce the Mix1Pro, a compact commercial machine aimed at indoor facilities below 53,800 square feet. That target matters. Smaller, messier sites are where autonomy can look terrific on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Enzyme Inhibitor Market Growth Forecast: US$ 5.9 Billion

Updated Category News Views 125

The Future of the Enzyme Inhibitor Market The enzyme inhibitor market is positioned for significant growth, projected to reach US$ 5.9 billion by 2034, following an estimated rise from US$ 2.8 billion in 2023. This impressive growth is driven by a compound annual growth rate (CAGR) of 7.1% over the next decade. Enzyme inhibitors, particularly angiotensin-converting enzyme...

Continue Reading
Li-Cycle Announces $15 Million Public Offering Insights

Updated Category News Views 213

Li-Cycle Announces $15 Million Underwritten Public Offering Li-Cycle Holdings Corp. (NYSE: LICY), a recognized leader in lithium-ion battery resource recovery, has unveiled details about its recent public offering. This strategically planned offering is projected to raise approximately $15 million for the company, providing essential funding to support its ongoing and...

Continue Reading
Investors Encouraged to Join Edwards Lifesciences Case

Updated Category News Views 117

Investors Encouraged to Join Edwards Lifesciences Case In recent developments, the Rosen Law Firm, a dedicated advocate for investor rights, is reaching out to individuals who purchased securities of Edwards Lifesciences Corporation (NYSE: EW) during a specified time frame. This outreach aims to inform these investors about their rights and potential avenues to seek...

Continue Reading
AtlasNova's $2.3M Funding to Transform Small Business Automation

Updated Category News Views 318

AtlasNova Secures $2.3 Million for Small Business Automation With the latest funding, AtlasNova is dedicated to enhancing the operations of small businesses, helping them leverage efficiencies that typically only larger corporations enjoy. Unlocking Potential Through Intelligent Automation AtlasNova has successfully secured a seed round of $2.3 million, enabling them to...

Continue Reading
Congressman Questions SEC's 'Digital Asset Security' Definition

Updated Category News Views 196

Congressman Ritchie Torres Questions SEC's Use of Terminology Representative Ritchie Torres, a Democratic representative from New York, has recently shared his concerns about the phrase "digital asset security" as used by the U.S. Securities and Exchange Commission (SEC). He’s particularly interested in the legal basis and origins of this term. Congressional Dialogue...

Continue Reading